Medical and Health News - MediPaper Medical Communications Ltd.

19th February 2020

Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

Adding capivasertib to paclitaxel improved the progression-free survival (PFS) in patients with metastatic triple-negative breast cancer (TNBC) who had not received prior treatment for metastatic disease. Predominantly patients with PIK3CA/AKT1/PTEN-altered tumours had a more pronounced PFS and overall survival (OS) benefit, as reported by Schmid et al. in the Journal of Clinical Oncology

Capivasertib combined with paclitaxel improves survival of metastatic triple-negative breast cancer patients

11th February 2020

Capivasertib plus paclitaxel improves survival of metastatic triple-negative breast cancer patients

24th January 2020

Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

ADDING RIBOCICLIB TO FULVESTRANT IMPROVES THE SURVIVAL OF ADVANCED BREAST CANCER PATIENTS MONALEESA-3

12th January 2020

Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer

ASCO 2019 lung cancer NSCLC ASCO19 SCLC mesothelioma KEYNOTE-189 KEYNOTE-001 IMpower150 MYSTIC LCMC3 Lung-MAP S1400G S1400I Flaura CALGB 30901 DETERRED COMPASS

12th June 2019

ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised

paclitaxel, cobimetinib, Cotellic, MEK, Exelixis, atezolizumab, Tecentriq, nab-paclitaxel pembrolizumab, Keytruda, Merck, MSD, eribulin mesylate, Halaven, pertuzumab, trastuzumab, Herceptin, Perjeta, docetaxel, Taxotere, Sanofi, trastuzumab-dkst, Ogivri, Mylan, Biocon, margetuximab, MacroGenics, capecitabine, Xeloda, Genentech, gemcitabine, Gemzar, vinolrebine, pyrotinib, Jiangsu HengRui Medicine, neratinib, Nerlynx, Puma, lapatinib, Tykerb, carboplatin, T-DM1, ado-trastuzumab emtansine, Kadcyla doxorubicin, cisplatin, olaparib, Lynparza, cyclophosphamide, epirubicin, Ellence, Pharmorubicin, letrozole, Femara, Novartis, AI, NSAI, capivasertib, capivasertib, AZD5363, AKT, hormonal therapy, endocrine therapy, CDK4/6, RAD001, mTOR, fulvestrant, Faslodex, abemaciclib, Verzenio, Eli Lilly, ribociclib, Kisqali, goserilin, Zoladex, AstraZeneca, everolimus, Afinitor, exemestane, Aromasin, Pfizer, palbociclib, Ibrance, #ASCO2019, AKT1, AZ, BRCA, chemotherapy, CNS metastases, ER-positive, ESR1, GnRH, HER2-negative, HER2-positive, HR-positive, LABC, neoadjuvant, OfS, PARP, PARPi, pCR, PD-L1, postmenopausal, PR-positive, premenopausal, RB1, TAC, taxane, TNBC, trastuzumab, triptorelin

3rd June 2019

ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

24th April 2019

KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer

腫瘤學新知 | CANCER INFORMER HONG KONG

《漫談腦癌》第五集 – 腦癌的外科手術(一) 【視頻】
在清醒的狀態下進行腦科手術？聽起來不可思議，但這些都是腦癌外科手術的進步。 Read more »
Source: 腫瘤學新知 | Cancer Informer Hong Kong | Published: 17th February 2020 - 2:22 PM
陪你度癌關——生死相依
莊周妻死，鼓盆而歌，因為莊周認為生死猶如四季交替，周而復始。如今妻子安息於天地之間，活着的人實在沒必要哭哭啼啼，否則就太不通達天理了。當然，現實中能有莊周的境界者太少了。從容面對生離死別，談何容易？ Read more »
Source: 腫瘤學新知 | Cancer Informer Hong Kong | Published: 17th February 2020 - 9:34 AM
陪你度癌關——與孩子談論癌症
阿韶與妻子青梅竹馬，婚後育有一女，五歲的女兒是他的掌上明珠，他是女兒心目中的巨人，一家三口樂也融融，幸福美滿。可惜好景不常，阿韶被確診患上肺癌。起初，他鬥志高昂，為了心愛的妻女，他積極接受治療，並深信自己一定能完全康復。住院期間，他不忍心女兒看見自己一臉病容，影響自己在女兒心目中的「巨人」形象，他選擇向女兒隱瞞病況，更拒絕妻子帶女兒前來探望。他堅信自己很快便能康復出院，回復昔日狀態共聚天倫。 Read more »
Source: 腫瘤學新知 | Cancer Informer Hong Kong | Published: 10th February 2020 - 9:45 AM
唔 check 唔知身體好
有時覺得都係做男人好, D 女人嘢真係好鬼奄悶。 2018 年有感一把年紀都未做過 breast screening, 於是走去做 USG 同… Read more »
Source: 腫瘤學新知 | Cancer Informer Hong Kong | Published: 10th February 2020 - 9:39 AM